Risk Factors Update Summary
- Uncertainty about achieving satisfactory prices for products using virtual reality technology, impacting margins.
- Introduced new products in the neurovascular market since 2007, with additional products in 2013, 2014, and 2020.
- Transition to a new ERP software system, requiring continued capital investment and potential operational disruptions.
- Operating losses incurred in 2020 and 2021, with uncertainty about achieving satisfactory pricing.
- Expansion of international sales, with a focus on growing non-U.S. markets and addressing global trade challenges.
- Increased investment in immersive healthcare products, including hiring new personnel and consultants.
- Increased investment in developing and commercializing immersive healthcare products using virtual reality technology.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1321732&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.